Evenity (Romosozumab) Pediatric School and Activity Considerations for Children Under 12

Why Romosozumab Is Used in Young Children

Romosozumab works by inhibiting sclerostin, a protein that normally suppresses bone formation. Blocking sclerostin increases bone-mineral density (BMD) faster than any currently available bisphosphonate in adult trials, which is why pediatric bone specialists are investigating it for children with catastrophically low BMD. The drug is not yet FDA-approved for patients under 18, but named-patient and compassionate-use protocols exist in the United States, Europe, and Japan.

The Conditions That Bring Children to This Drug

Osteogenesis imperfecta (OI) is the most common reason a child under 12 might receive romosozumab. OI type III produces progressive bone deformity and fracture rates that bisphosphonates alone cannot fully control. A 2021 case series published in Bone (PMID 33964553) described lumbar spine BMD Z-scores of -4.0 to -6.0 in children with OI type III before treatment, scores incompatible with safe participation in ordinary classroom activities without structural accommodations. [1]

Children with glucocorticoid-induced osteoporosis, immobilization osteoporosis from cerebral palsy, or rare conditions such as chronic recurrent multifocal osteomyelitis may also reach the threshold where a bone-forming agent is considered after bisphosphonates fail.

What the Pediatric Data Currently Show

Adult phase-3 trial data for romosozumab are well-established. The FRAME trial (N=7,180) showed a 73% reduction in new vertebral fracture risk versus placebo at 12 months (P<0.001). [2] The ARCH trial (N=4,093) showed a 48% reduction in new vertebral fracture versus alendronate. [3] No equivalent phase-3 pediatric RCT exists yet. NCT04907513 (CRSTAL-OI) is an ongoing phase-2 trial enrolling children 5-17 with OI types III and V, and interim data are expected in 2026. [4]

Because the pediatric evidence base is still forming, every clinical decision about school and activity must be made by the child's treating team, not from package-insert language alone.

School Nurse and Administrative Coordination

The school environment presents specific risks for children on romosozumab. A school nurse who understands the treatment context can prevent fractures and manage injection logistics without pulling the child out of class unnecessarily.

Setting Up the Health Plan

Before the first day of school during the treatment course, the family and prescribing physician should provide the school nurse with a written individualized health plan (IHP) that covers three areas: the monthly injection schedule, fall-prevention protocols, and an emergency fracture response plan. The Endocrine Society's 2023 clinical practice guideline on pediatric bone health recommends that any child receiving anabolic bone therapy have a written school health plan reviewed annually. [5]

The IHP should name the child's orthopedic or metabolic bone specialist, provide a 24-hour contact number, and specify which activities require a spotter or are off-limits entirely. A single page is not enough. The plan should be detailed enough that a substitute nurse can follow it without a phone call.

Injection-Day Considerations

Romosozumab is administered as two simultaneous subcutaneous injections (105 mg each, abdomen or thigh) once monthly. Injections in pediatric protocols are typically given in a clinic, not at school. Still, the 24-48 hours after injection may bring mild injection-site reactions (bruising, swelling, tenderness) in up to 18% of patients in adult data. [2] The school nurse should document any injection-site findings reported by the child and flag them to the prescribing team.

Injection days should ideally fall on a Thursday or Friday so that any post-injection fatigue or myalgia resolves over the weekend. If a child attends school within 24 hours of injection, gym class and recess should be modified to low-impact activities that day.

Emergency Fracture Protocol

Children with severe OI can fracture from forces as minor as a peer bumping into them in a hallway. The school nurse and at least two classroom teachers should know the fracture emergency protocol:

• Do not move the child until emergency services arrive or a clinician instructs otherwise.
• Immobilize the suspected limb with whatever is available (rolled jacket, pillow, padded board).
• Call 911 first, then the parents, then the treating orthopedic surgeon.
• Document the mechanism of injury in detail for the bone specialist.

The American Academy of Pediatrics supports written emergency action plans for children with bone fragility disorders in its policy statement on care of children with OI. [6]

Physical Activity Guidelines During Romosozumab Treatment

Activity restrictions for a child on romosozumab depend on the underlying diagnosis, baseline BMD Z-score, fracture history, and how many months of treatment have been completed. There is no single published pediatric activity protocol for romosozumab specifically, but bone-loading principles from bisphosphonate OI literature translate reasonably well.

Weight-Bearing Activity and Bone Stimulus

Weight-bearing mechanical load is anabolic for bone. The combination of mechanical loading and sclerostin inhibition may be additive in theory, because both converge on Wnt signaling pathways that drive osteoblast activity. A 2019 review in JBMR Plus (PMID 31687650) found that progressive weight-bearing programs in children with OI during bisphosphonate therapy produced incremental BMD gains beyond the drug effect alone. [7] The same principle likely applies to romosozumab, though direct trial data are absent.

The practical implication: gentle, supervised weight-bearing activity (walking, standing frames, hydrotherapy) should be maintained or introduced during the treatment course, not eliminated. Total immobilization is counterproductive.

Activities to Restrict or Avoid

Certain activities carry unacceptable fracture risk for children with very low BMD, regardless of treatment phase. These include:

• Full-contact team sports (football, rugby, wrestling, hockey)
• Gymnastics with aerial elements or unassisted bar work
• Trampoline use (including gym-class bouncing)
• Unsupervised cycling on uneven terrain
• High-impact running on hard surfaces until BMD Z-score improves to above -2.5

The Osteogenesis Imperfecta Foundation's activity guidelines recommend that children with OI who have a Z-score below -3.0 participate in gym class only in a modified, non-impact capacity with direct adult supervision. [8]

Graded Return to Normal Activity

Activity restrictions should decrease as BMD improves. A practical framework used by many pediatric bone centers, though not yet published as a formal protocol, involves three phases tied to lumbar spine Z-score thresholds:

Phase 1 (Z-score below -3.5): Aquatic therapy, standing frame, supervised walking with assistive device. No gym class. School desk work only, with wheelchair or adaptive seating available.

Phase 2 (Z-score -2.5 to -3.5): Walking without device on flat surfaces, seated adaptive PE, hydrotherapy, light resistance band work with physiotherapist. Gym class with full-time aide and modified activity plan.

Phase 3 (Z-score above -2.5): Low-impact sport (swimming, cycling on flat surfaces, yoga). Standard gym class with specific exclusions (no contact, no jumps). Annual reassessment by bone specialist before any sport upgrade.

Z-score targets should be confirmed by DXA at 6 and 12 months into the romosozumab course. The International Society for Clinical Densitometry (ISCD) recommends using age- and sex-matched Z-scores (not T-scores) for all pediatric BMD interpretation. [9]

Calcium, Vitamin D, and Nutrition During the School Day

Romosozumab increases bone formation rapidly. That rapid mineralization demands adequate substrate. Hypocalcemia has been reported with romosozumab in adults who had vitamin D deficiency at baseline, and in children with renal impairment, the risk is higher. [2]

Daily Targets by Age

For children aged 4-8, the NIH recommends 1,000 mg elemental calcium daily. For ages 9-13, the target rises to 1,300 mg. Vitamin D requirements are 600 IU daily for ages 1-13 per the Institute of Medicine, though many pediatric bone specialists target 800-1,000 IU in children with malabsorption or limited sun exposure. [10]

A school lunch that includes milk, cheese, or yogurt provides roughly 300-400 mg calcium. Parents should review the school menu and supplement at home to meet the daily total. Calcium carbonate (cheapest, food-dependent absorption) or calcium citrate (absorption independent of food) can be split into 500 mg doses twice daily, since single doses above 500 mg are absorbed less efficiently.

Teacher Awareness of Dietary Needs

The child's 504 plan or IHP should note the calcium requirement so that a teacher does not inadvertently discourage a second milk carton at lunch. This sounds minor. In a child receiving an anabolic bone agent, a consistent calcium deficit over a 12-month treatment course could blunt BMD response. A 2020 study in Osteoporosis International (PMID 32632625) found that calcium intake below 700 mg/day during bisphosphonate therapy in children with OI reduced lumbar spine BMD gains by 23% compared to children meeting targets. [11]

Monitoring Schedule and What School Staff Should Know

Routine monitoring for children on romosozumab includes DXA scans, serum calcium, phosphate, PTH, bone-turnover markers (P1NP and CTX), and a basic metabolic panel. These appointments typically occur at baseline, 3 months, 6 months, and 12 months.

Appointment Absences

Families should inform the school at the start of the academic year that the child will have approximately four to five medical absences for monitoring visits. Most pediatric bone centers schedule these in outpatient settings that take 2-3 hours. The school should classify these as medically excused absences and provide homework in advance.

Signs That Require Immediate School Nurse Notification

Teachers and school nurses should be trained to recognize potential hypocalcemia symptoms, which include muscle cramps, perioral tingling, and carpopedal spasm. While frank hypocalcemia is rare in vitamin D-replete children, the risk is not zero. A 2022 FDA drug safety communication updated the romosozumab label to reinforce calcium and vitamin D supplementation requirements and flag hypocalcemia risk. [12]

Other signs requiring nurse notification include new-onset limb pain (possible stress or low-trauma fracture), sudden difficulty ambulating, or swelling at any injection site persisting beyond 72 hours.

Communication Between School and Prescribing Team

A monthly brief written update from the school nurse to the prescribing physician, describing activity participation level, any injuries, and any symptoms noted, takes 10 minutes to write and may prevent delayed fracture diagnosis. The HealthRX medical team recommends a standardized one-page monthly check-in template, which should be created at the start of the treatment course and filed in the child's school health record.

Psychosocial Considerations for the School-Age Child

Bone disease at age 5-11 is not just a physical problem. Children who cannot participate in full recess, gym class, or birthday-party activities face real social exclusion risks.

Talking to Classmates

A brief, age-appropriate classroom conversation led by the school nurse or the child's parent (with the child's consent) can reduce peer confusion about why one student cannot play tag or jump on the trampoline. Framing the explanation around "bones that are getting stronger with medicine" rather than "bones that break easily" is less stigmatizing and more accurate for children on an anabolic therapy.

The American Psychological Association's guidance on chronic illness in school-age children notes that peer education reduces bullying and increases inclusion behavior in classrooms where a child has a visible physical difference or activity limitation. [13]

Supporting the Child's Sense of Control

Children under 12 process medical information concretely. Letting the child keep their own simple chart of their activity milestones ("I walked to the library without my walker today") reinforces the therapeutic progress and gives them ownership over their recovery. This approach aligns with the family-centered care model endorsed by the Society for Pediatric Psychology in its 2021 practice guidelines. [14]

Involvement in age-appropriate decisions, such as choosing the music played during injection prep at the clinic, or selecting which modified activity they do in PE, reduces procedure-related anxiety and improves adherence to the treatment schedule.

Transition Planning as the Treatment Course Ends

The standard investigational romosozumab course in pediatric protocols mirrors the adult course: 12 months of monthly injections. After that, most centers transition to an antiresorptive (typically zoledronic acid or denosumab) to consolidate gains, because the BMD benefit from romosozumab can partially reverse if no follow-on therapy is used, as seen in the FRAME extension data. [2]

School Plan Updates at Treatment End

At the 12-month mark, the bone specialist should provide the school with an updated activity clearance letter. This letter should specify any continuing restrictions, the follow-on therapy if applicable, and revised emergency fracture protocols. Activity restrictions during zoledronic acid consolidation are generally less strict than during the romosozumab course, but this depends on whether the child reached Phase 2 or Phase 3 Z-score thresholds.

Long-Term DXA Follow-Up and Activity Re-Clearance

DXA should be repeated 6 months after the final romosozumab injection to confirm that BMD is being maintained by the antiresorptive. If lumbar spine Z-score has improved to above -2.0, many pediatric bone centers formally clear the child for broader sport participation, including supervised low-contact activities. This clearance should be in writing, dated, and kept in the school health file.

The ISCD 2019 pediatric position statement specifies that serial DXA in children should use the same scanner and acquisition software at each visit to ensure longitudinal precision. [9] Families should confirm that the school district's records reflect the most recent DXA results so that activity decisions are based on current bone status, not on restrictions written 12 months earlier.